Researchers at Tufts University have designed a novel drug candidate targeting four hormone receptors—including GLP-1, GIP, and glucagon—to improve efficacy and safety in obesity management. This next-generation approach builds on existing incretin therapies, aiming to enhance appetite control, metabolic regulation, and glucose homeostasis. Early data suggest substantial promise for improved weight loss treatments.